Терапевтический архив (Jul 2009)

Trisomy of chromosome 8 in Ph-negative cells of the bone marrow in patients with chronic myeloid leukemia treated with inhibitors of BCR-ABL tyrosinkinases

  • Anna Grigor'evna Turkina,
  • Elena Vasil'evna Domracheva,
  • Aleksandra Valer'evna Vorontsova,
  • Elena Aleksandrovna Aseeva,
  • Ol'ga Yur'evna Vinogradova,
  • Ol'ga Veniaminovna Stakhina,
  • Galina Anatol'evna Gusarova,
  • Ol'ga Arkad'evna Dyagileva,
  • Elena Aleksandrovna Semenova,
  • Marina Vasil'evna Vakhrusheva,
  • Tamara Ivanovna Kolosheynova,
  • Evgeniy Mikhaylovich Abakumov,
  • Ekaterina Yur'evna Chelysheva,
  • Svetlana Rudol'fovna Goryacheva,
  • Tat'yana Vladimirovna Ivanova,
  • Elena Stanislavovna Zakharova,
  • Lyubov' Yur'evna Kolosova,
  • Adel' Vladimirovna Zakharova,
  • Irina Nikolaevna Naumova,
  • Larisa Vladimirovna Dyachenko,
  • Sergey Mikhaylovich Kulikov,
  • Lidiya Grigor'evna Kovaleva,
  • Nina Dmitrievna Khoroshko,
  • A G Turkina,
  • E V Domracheva,
  • A V Vorontsova,
  • E A Aseeva,
  • O Yu Vinogradova,
  • O V Stakhina,
  • G A Gusarova,
  • O A Dyagileva,
  • E A Semenova,
  • M V Vakhrusheva,
  • T I Kolosheinova,
  • E M Abakumov,
  • E Yu Chelysheva,
  • S R Goryacheva,
  • T V Ivanova,
  • E S Zakharova,
  • L Yu Kolosova,
  • A V Zakharova,
  • I N Naumova,
  • L V Dyachenko,
  • S M Kulikov,
  • L G Kovaleva,
  • N D Khoroshko

Journal volume & issue
Vol. 81, no. 7
pp. 29 – 36

Abstract

Read online

Aim. To analyse clinical implications of chromosome 8 trisomy in Ph-negative cells of the bone marrow in patients with chronic myeloid leukemia (CML) treated with inhibitors of tyrosinkinases (ITK). Material and methods. A total of 386 patients with CML (chronic phase - 288, acceleration phase - 77) received imatinib (400-800 mg/day). Because of resistance and/or intolerance some patients were switched to ITK II (nilotinib, dasatinib, bozutinib). This study included 8 CML patients (7 in a chronic phase, 1 in acceleration phase) treated with BCR-ABL ITK inhibitors of the first (imatinib) and the second line (ITK-II). The standard cytogenetic examination, on demand - investigation of the interphase nuclei with FISH, in some cases morphological, cytochemical and histological examinations of the bone marrow were made. Results. The existence of a Ph-negative clone with trisomy of chromosome 8 had no negative effect on the course of the disease. The patients showed a stable hematological and cytogenetic response and no need in changing treatment policy. In long-term follow-up Ph-negative clone with trisomy of the chromosome 8 persisted without a clear trend to rise in most patients. Conclusion. Detection of a Ph-negative clone with chromosome 8 trisomy at early stages suggests parallel existence of Ph-positive and Ph-negative clones. None of the patients had myelodisplasia.

Keywords